Improved understanding of cancer immunology has provided insight into the phenomenon of frequent tumor recurrence after initially successful immunotherapy. A delicate balance exists between the capacity of the immune system to control tumor growth and various resistance mechanisms that arise to avoid or even counteract the host's immune system. These resistance mechanisms include but are not limited to (i) adaptive expression of inhibitory checkpoint molecules in response to the proinflammatory environment and (ii) amplification of cancer stem cells, a small fraction of tumor cells possessing the capacity for self-renewal and mediating treatment resistance and formation of metastases after long periods of clinical remission. Several individual therapeutic agents have so far been developed to revert T-cell exhaustion or disrupt the cross-talk between cancer stem cells and the tumor-promoting microenvironment. Here, we demonstrate that a three-arm combination therapy-consisting of an mRNA-based vaccine to induce antigen-specific T-cell responses, monoclonal antibodies blocking inhibitory checkpoint molecules (PD-1, TIM-3, LAG-3), and antibodies targeting IL-6 and TGF-b-improves the therapeutic outcome in subcutaneous TC-1 tumors and significantly prolongs survival of treated mice. Our findings point to a need for a rational development of multidimensional anticancer therapies, aiming at the induction of tumor-specific immunity and simultaneously targeting multiple resistance mechanisms.
In recent years, the impact of cancer immunotherapy has burgeoned tremendously. Thus, its effect is no longer limited to the induction of potent tumor-specific immune responses and anecdotic clinical responses, but long-lasting control of tumor growth has now become an attainable goal. Nevertheless, with immunotherapy becoming increasingly popular, a growing body of evidence indicates that cancer relapse is driven by multiple resistance mechanisms that become activated in response to immunotherapy. [1] [2] [3] [4] A better understanding of those resistance mechanisms and a careful evaluation of combination therapies are therefore necessary to overcome the problem of recurrent tumor disease.
Several studies demonstrated that tumor-infiltrating T cells express inhibitory checkpoint molecules such as CTLA-4, PD-1, TIM-3 and LAG-3. Importantly, a subset of tumor-specific T cells that co-express two or more immune checkpoint molecules was shown to secrete less IFN-g and TNF-a as compared with their single positive counterparts. 5 Recently, a phenomenon called compensatory upregulation of immune checkpoint molecules has been reported. 6 In this regard, blockade of one of the immune checkpoint molecules will lead to the upregulation of the other(s), as commonly observed across different tumor types. [6] [7] [8] This could explain the limited therapeutic efficacy of a single agent anti-PD-1 or anti-PD-L1 antibodies observed in cancer patients. 9, 10 In this context, several preclinical and clinical studies demonstrated synergistic effect of combinatorial blockade of two or more immune checkpoint molecules. [5] [6] [7] 11 Nevertheless, although checkpoint inhibitors are considered a revolution in the immunotherapy of cancer, depending on the tumor type, the majority of patients remain resistant to this therapy or relapse over time. 12 Thus, as previously observed for cancer vaccines, only targeting one side of the balance will not be sufficient and therefore alleviating inhibition by checkpoint inhibitors will need to be combined with stimulating the immune system, using anticancer vaccines. 13 Another hurdle for durable cancer therapies are the socalled cancer stem cells (CSCs). These represent a rare population of cells with stem cell-like characteristics, lurking within treated primary tumor beds and initiating tumors at distant sites, often after long periods of clinical remission. 14 More importantly, they are thought to be resistant to conventional anticancer therapies including chemotherapy and radiotherapy. 15 Sox2 is a key gene encoding a master transcription factor implicated in maintaining the stemness of embryonic stem cells and appears to become reactivated in several human cancers including glioblastoma multiforme, breast cancer, bladder cancer, lung cancer and ovarian cancer. 16, 17 Interestingly, preclinical data indicate that both CD4
1 and CD8 1 T-cell immune responses can be raised against murine CSCs. 18, 19 The feasibility of this approach is confirmed by the fact that the human immune system is capable of mounting spontaneous immune responses against SOX2 and OCT3/4, another stemness factor. 20, 21 It has been demonstrated that different phenotypic and functional attributes of CSCs can be reversibly turned on and off in response to the microenvironmental ecology of the tumor. Hence, one may postulate that CSCs represent a cell population that transiently acquires stemness abilities rather than being a well-defined subpopulation of cancer cells with an invariable phenotype and characteristics clearly distinguishing them from the bulk of the tumor. 22 For instance, the proinflammatory cytokine IL-6 has been shown to directly regulate the stemness of tumor cells, promote bone metastasis and cancer progression 23 (most likely via the STAT3 pathway 24 ). Similarly, TGF-b, which is abundantly present in many tumors, has been demonstrated to increase the numbers of CSCs via cancer cell dedifferentiation. 25, 26 It is not without reason that both IL-6 and TGF-b have recently been defined as biomarkers of tumor malignity and radioresistance. 27 Therefore, it has been suggested that CSCs could be indirectly eradicated by disrupting their relationship with the TME.
In this work, we aimed at improving the therapeutic efficacy of mRNA-based therapy using the TC-1 model of HPVderived cancers. In the first instance, we evaluated whether blocking various inhibitory checkpoint molecules (PD-1, TIM-3 and LAG-3) could boost tumor-specific immune responses. As an efficient anticancer therapy is associated with the amplification of cancer stem cells, our next approach focused on targeting the CSCs. Here we evaluated two possibilities: (i) the induction of SOX2-specific T-cell responses in order to directly eradicate the CSCs and (ii) the disruption of the IL-6/TGF-b pathway to interrupt the cross-talk between TME and CSCs. Here, we demonstrate that the induction of T cells specific for SOX2 is not associated with survival benefit in the therapy of long-established primary tumors. In contrast, a simultaneous blockade of inhibitory checkpoint molecules, IL-6 and TGF-b significantly prolongs survival and leads to a complete tumor rejection in 23% of treated mice without signs of overt autoimmunity.
Materials and Methods

Mice
All in vivo experiments were performed in accordance with the Belgian law (KB 29/05/2013) and the EU Directive 2010/63/ EU, under license LA 1230214 and approved by the Ethical Review Body for animal welfare of Vrije Universiteit Brussels, using guidelines outlined by Workman et al.
28 C57BL/6 mice were supplied by Charles River Laboratories (L'Arbresle Cedex, France) at 6 weeks of age and with a body weight of > 18 g and What's new? Tumors can become resistant to immunotherapy via multiple mechanisms, necessitating a search for new therapeutic approaches to combat recurrent tumor disease. Here, single combination therapy of an mRNA vaccine with inhibitors of either immune checkpoint molecules or the IL-6/TGF-b pathway was investigated in a TC-1 tumor cell mouse model. The combination of mRNA vaccine with either of the other agents showed limited therapeutic efficacy in a long-established TC-1 tumor model. By contrast, the three approaches together-IL-6/TGF-b pathway disruption, concurrent blockade of three different immune checkpoint molecules, and mRNA-based anticancer immunotherapy-significantly improved therapeutic control of longestablished tumors.
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were housed in Tecniplast Green Line IVC Sealsafe cages holding a maximum of 4 animals with steam sterilized aspen chip bedding, Nestlets nesting material, a cardboard tunnel and wooden chew blocks. Mice were housed on a 14/10 light/dark cycle, with ad libitum acidified water and RM1 rodent diet.
Tumor cell lines
TC-1 cells (kind gift from Dr. Denise Nardelli-Haefliger, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland) were cultured in RPMI 1640 supplemented with 10% fetal calf serum, 100 IU penicillin, 100 lg/mL streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, nonessential amino acids and 0.4 mg/mL G418.
B16-F0 cells were cultured in RPMI 1640 medium (SigmaAldrich, USA) supplemented with 5% fetal calf serum, 100 U/mL penicillin, 100 lg/mL streptomycin, 1 mM sodium pyruvate, nonessential amino acids and 0.1% b-mercapto-ethanol.
Inoculation of tumor cells
Prior to inoculation, the tumor cells were counted using a CASY cell counter (OLS OMNI Life Science) and the cell viability was verified by flow cytometry using 7-AAD. C57BL/6 female mice were anesthetized with 5% isoflurane and 50,000 TC-1 tumor cells or B16-F0 sorted cancer stem cells or bulk cells were administered subcutaneously in a volume of 50 lL sterile, ice-cold PBS.
Cancer stem cell staining
Cancer stem cell staining was based on the protocol described by William Telford with minor modifications. 29 Briefly, cells of interest (e.g., tumor cells or bone marrow cells) were suspended in culture medium at a density of 10 6 cells/mL. The cells were subsequently passed through a 40 lm nylon filter and 10 lM Vybrant TM DyeCycle TM Violet (Invitrogen) was added. The cells were incubated for 90 min (agitated every 10 min) at 378C in 5% CO 2 . To allow appropriate gating of the CSC population, an ABC pump inhibitor, reserpine (Sigma-Aldrich), was used as a control. To that aim, 10 6 cells suspended in 1 mL of culture medium was first incubated for 30 min with 100 lM reserpine. Afterward, 10 lM Vybrant TM DyeCycle TM Violet (Invitrogen) was added to the control samples and the cells were incubated for 90 min (agitated every 10 min) at 378C in 5% CO 2 .
After the incubation, the tumor cells were washed twice with ice-cold PBS. The samples were kept on ice until the moment of analysis. For flow cytometric analysis, first, the FSC and SSC were adjusted to exclude doublets. Next, viable cells were selected based on the absence of 7-amino-actinomycin (7-AAD) signal and the appropriate voltages for the Red (635LP 670/30BP) and Blue (450/50BP) channels were chosen.
Adherent tumor cells were detached using in house prepared detaching medium: the following mixture of compounds was added to 500 mL sterile PBS (Sigma-Aldrich, USA): NaCl (4,000 mg, Sigma-Aldrich, USA), KCl (200 mg, Acros Organics, Belgium), NaH 2 PO 4 (37.8 mg, Acros Organics, Belgium), Na 2 HPO 4 (60.25 mg, Acros Organics, Belgium), HEPES (1190 mg, Sigma-Aldrich, USA), NaHCO 3 (175 mg, Merck, Germany), EGTA (95 mg, Sigma-Aldrich, USA) and D-(1)-Glucose (450 mg, Acros Organics, Belgium).
Plasmids and messenger RNA
The formulation of E7-TM (TriMix) vaccine was described previously. 30 The sequence encoding the full-length human SOX2
protein (NCBI Reference Sequence: NG_009080.1) was cloned in-frame between the signal sequence and the transmembrane and cytoplasmic regions of human DC-LAMP. This chimeric gene was cloned in the pST1 plasmid that was linearized with SapI restriction enzymes prior to in vitro transcription. In vitro mRNA transcription and quality control were performed as described previously. 31 Prior to immunization, the mRNA solution was prepared as described. 32 Treatment regimens
1.
Intranodal immunizations were performed as described previously. 32 In brief, mice were anesthetized with ketamine-xylazine solution by intraperitoneal injection. The fur on the area of surgical manipulation was shaved and a small incision was made above the subiliac lymph node. Once the lymph node was exposed, the mRNA solution was injected (10 lL) and the wound was closed with surgical suture. The immunizations were repeated with 5-day intervals. 2. For chemotherapy approach, the mice were treated with Cisplatin given intraperitoneally in four doses of 4 mg/kg on day 10, 11, 18 and 19 post tumor inoculation. 3. For radiotherapy approach, the mice were anesthetized with ketamine-xylazine solution by intraperitoneal injection. The dose of 21 Gy was delivered on the tumor area in three fractions of 7 Gy given on day 10, 15 and 20 post tumor inoculation.
Preparation of single-cell suspension from implanted mouse tumors
The preparation of a single-cell suspension of implanted tumors was performed according to a protocol of Miltenyi Biotec. Briefly, tumors were cut into small pieces of 5 mm and transferred to a gentleMACS C tube containing 5 mL RPMI 1640. Subsequently, the tumors were homogenized on the gentleMACS Dissociator and after the addition of Collagenase I (10,000 U/mL) and Dispase II (32 mg/mL), the suspension was incubated for 40 min at 378C. After this incubation step, the suspension was homogenized a second time on the gentleMACS Dissociator and filtered through a 70 lm nylon filter (BD Falcon). After 5 min of centrifugation at 1500 rpm, the erythrocytes were lysed with 5 mL red blood cell lysis buffer (0.16 M NH 4 Cl, 0.17 M Tris, pH 7.2) for 2 min, the lysis buffer was then neutralized with 10 mL PBS. The cells were centrifuged for 5 min at 1500 rpm and then resuspended in culture medium at a density of 10 6 cells/mL.
ELISA
Splenocytes derived from previously immunized mice or naive control mice were counted and transferred to a 96 well plate (0.2 million cells/well). The cells were restimulated with antigenic peptides in the presence of human IL-2 (25 IU/mL, Thermo Fisher Scientific) for 72 hr. Supernatants were collected and the secretion of IFNg was assessed using a commercially available ELISA kit (Mouse IFN-g ELISA, eBioscience) according to the manufacturer's instructions.
Peptides
SOX2 peptides (a total of 86 15-mer peptides overlapping with 11 amino acids) were ordered at EMC Microcollections GmbH (Germany) and were distributed over 4 peptide pools, each of which was further split into 4 subpools consisting of 4-5 individual peptides. For IFN-g ELISA and in vivo CTL assay, the peptides were used at a final concentration of 2.2 lg/mL for each individual peptide. The H2-K b restricted ovalbumin (SIINFEKL) and E7 (RAHYNIVTF) peptides were ordered at Kaneka Eurogentec S.A. (Belgium) and were used at a final concentration of 5 lg/mL.
Colony-forming assay
A base layer of 0.5% agar dissolved in RPMI 1640 was poured into 6-well plate. Cells were seeded in the number of 2,000 or 10,000 per well on the top layer of 0.35% agar and cultured for 2 weeks at 378C, 5% CO 2 in a humidified incubator. After two weeks, colonies were visualized with use of crystal violet and counted under the microscope.
In vivo CTL assay
Splenocytes from donor mice were suspended in RPMI 1640 medium at a density of 10 3 10 6 /mL and split into two tubes. E7 peptide was added to one tube at a final concentration of 5 lg/mL and both cell suspensions were incubated at 378C for 1.30 hr. Cells were washed twice with RPMI 1640 medium and resuspended in PBS at concentration 10 3 10 6 /mL. The E7-loaded population was subsequently stained with a high concentration (1.5 lM) of CellTrace TM Violet (CTV, ThermoFisher Scientific), while the antigenfree population was stained with a low (0.15 lM) concentration of CTV. The cells were then incubated at 378C for 20 min and washed twice with RPMI 1640 medium. Afterward, the cell pellets were resuspended in PBS, mixed in equal proportions and administered intravenously into the recipient mice (200 lL per mouse). Blood samples were collected from the tail vein 18 hr later and the percentage of in vivo lysis was evaluated by flow cytometry.
Monoclonal antibodies
The Total RNA isolation and cDNA synthesis
The isolation of total RNA was performed using the SV Total RNA Isolation System (Promega) according to the manufacturer's instructions. Eluted total RNA was stored at 2808C until cDNA synthesis. For cDNA synthesis the First Strand cDNA synthesis kit was used (Thermo Scientific). Briefly, 1 lL of random hexamer primers was added to 11 lL of RNA sample in a nuclease-free tube on ice. Consequently, 1 lL of RNAse inhibitor (20 U/lL), 2 lL dNTPs, 1 lL RT (200 U/lL) and 4 lL reaction buffer were added to every sample, gently mixed and centrifuged. Samples were incubated for 5 min at 258C followed by 60 min incubation at 428C. The reaction was terminated by heating at 708C for 5 min and samples were stored at 2208C.
qRT-PCR
Quantitative reverse transcriptase PCRs were performed using a CTX Connect TM Real-Time System (BioRad). Hard-Shell 
Recombinant cytokines
Recombinant mouse IL-6 (carrier-free) was ordered from BioLegend Inc. (USA) and used at a final concentration of 50 ng/mL. Recombinant mouse TGF-b 1 protein was ordered from eBioscience Europe and used at a final concentration of 10 ng/mL.
Flow cytometry
Flow cytometry-based experiments were performed using an LSRFortessa (BD Biosciences). The data were analyzed using BD FACSDiva software, version 8.01. The following antibodies were used in this study: CD45-BV605 (clone 30-F11, BioLegend), CD3-PacificBlue (clone 500A2, BD Biosciences), CD4-AlexaFluor700 (clone RM4-5, BD Biosciences), CD8-FITC (clone 53-6.7, BD Biosciences), CD8-APC-H7 (clone 53-6.7, BD Biosciences), CD11c-AlexaFluor700 (clone HL3, BD Biosciences), CD11b-FITC (clone M1/70, BD Biosciences), Ly6C-PECy7 (clone AL-21, BD Biosciences), Ly6G-PECF594 (clone 1A8, BD Biosciences), CD25-APC-Fire750 (clone PC61, BioLegend), CD127-PECF594 (clone SB/199, BD Biosciences), FoxP3-APC (clone 3G3, ThermoFisher Scientific), TIM3-PE (clone 8B.2C12, eBioscience), LAG3-PerCPeFluor710 (clone C9B7W, eBioscience), PD1-PECy7 (clone J43, eBioscience) and CTLA4-APC-R700 (clone UC10-4F10-11, BD Biosciences).
APC-conjugated E7-dextramers (H2-D b restricted, RAHY-NIVTF) were ordered at Immudex (Denmark).
Cell sorting
Cell sorting was performed by an FACSAria III (BDBiosciences) B16-F0 tumor cells were stained as described above. After washing, the cells were resuspended in sort medium (RPMI 1640 containing 1% FCI and 2 mM EDTA, SigmaAldrich, USA) and kept on ice until sort on the FACS Aria III (BD, Belgium) using violet diode laser 405 nm. Viable cells were selected based on 7-AAD signal and the events were plotted on Red (635LP 670/30BP) versus Blue (450/ 50BP) laser dot plot. The cells were sorted using a nozzle with a diameter of 85 lm at 45 PSI.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 7.3 for Windows. An unpaired Student's t test or one-way ANOVA followed by Turkey's multiple comparison test were used for all inference analyses. Survival data were analyzed using log-rank tests.
Results
Long-established TC-1 tumors relapse after initially successful immunotherapy
In our previous work, we demonstrated that subcutaneous TC-1 tumors regrow even after induction of strong tumorspecific immune responses (Figs. 1a and 1b) . 30 Therefore, in the first instance, we wanted to verify whether the therapeutic outcomes could be further improved by continued therapy with E7-TM mRNA. Mice bearing long-established TC-1 tumors were immunized either three (i.e., our standard vaccination regimen) or six times with E7-TM mRNA (Figs. 1c  and 1d ). Our data demonstrate that independently of the number of immunizations, tumors regrow, ultimately leading to death of all treated animals. This finding is in line with earlier discoveries by other groups indicating that besides the induction of tumor-specific immunity, tumor resistance mechanisms need to be targeted for the host to be able to productively battle against the tumor.
Expression of inhibitory checkpoint molecules on the surface of TILs is associated with their impaired function in vivo
Inhibitory checkpoint molecules are one of the many resistance mechanisms utilized by tumors to evade the existing host immunity. We investigated the expression of inhibitory checkpoint molecules on the surface of the tumor-infiltrating E7-specific T cells. Mice were immunized three times with E7-TM mRNA and 9 days later, an in vivo CTL assay was performed and the expression of checkpoint molecules by the TILs was investigated. More than 80% of E7-specific TILs cells expressed three out of four tested inhibitory molecules, namely, PD-1, TIM-3 and LAG-3 (Fig. 2a) . We observed an inverse correlation between the expression level of inhibitory molecules and the in vivo lytic capacity of T cells (Fig. 2b) . Combination therapy of E7-TM immunization and checkpoint inhibition in a shifted regimen (i.e., Day 22, 26 and 30 post tumor inoculation, starting 10 days after the first immunization) did not result in better therapeutic effect (Figs. 2c-2e) . Thus, in this particular setting tested, the checkpoint inhibitors do not provide any added benefit to the E7-TM vaccine. Importantly, this treatment regimen was not associated with any signs of toxicity such as depigmentation, hair loss or weight loss.
Amplification of CSCs is a consequence of efficient anticancer therapy
Next, we evaluated whether the presence of CSCs could be one of the reasons for the limited therapeutic efficacy of the anticancer therapy. To distinguish and sort out the putative CSCs, we used a functional flow cytometry assay that was originally proposed by Goodell et al. 33 and further optimized by Telford et al. 34 Here, we call this technique "cancer stem cell staining" and use a cell permeable DNA binding dye Vybrant TM DyeCycle TM Violet (DCV)-a dye that can be excited by a violet laser and is pumped out by the ABCG2 transporters that have been demonstrated to be responsible for tumor cell resistance to chemotherapeutic agents. 35 This dyeefflux assay (also called "side population assay") is widely used for the analysis of stem cells and progenitor cells and has been validated ex vivo by our group on bone marrow cells and in vitro and in vivo on B16 tumor cells (Supporting Information, Fig. 1 ). To investigate the effect of antitumor therapies on the CSC fraction, we subjected the TC-1 tumor-bearing mice to treatment with E7-TM, cisplatin or g-radiation. The tumor nodules were subsequently isolated and stained for the presence of CSCs. We found that similar to the effect exerted by chemotherapy and radiotherapy, immunotherapy led to an increase in the percentage of CSCs (Figs. 3a and 3b) .
As SOX2 is one of the key transcription factors expressed by CSCs, we evaluated the expression of Sox2 after the treatment with E7-TM (Fig. 3c) . E7-TM immunotherapy led to an increased Sox2 expression. To test whether SOX2 could be immunologically targeted, na€ ıve C57BL/6 mice were immunized with SOX2-TM and an in vivo CTL assay and ELISA were performed. We identified at least two highly immunogenic regions of this protein (Fig. 3d and Supporting Information, Fig. 2 ). We then immunized TC-1-bearing mice with SOX2-TM, E7-TM or E7-SOX2-TM mRNA and tumor growth and survival were monitored (Figs. 3e and 3f ). In accordance with data obtained by other groups, our data demonstrate that although SOX2-specific T-cell immune responses can be raised, they do not have an impact on the efficacy of E7-TM immunotherapy, which could be due to the fact that CSCs express lower levels of MHC I ( Supporting Information, Fig. 3 ).
21,36
Blockade of IL-6/TGF-b pathway decreases the number of CSCs in vitro but not in vivo It has been proposed that the TME can exert control over the CSCs via soluble factors, such as IL-6 and TGF-b. 37 We
Tumor Immunology and Microenvironment therefore decided to explore whether the stemness characteristics of the TC-1 tumor cell would be affected by exposure to mouse recombinant IL-6 and/or TGF-b in vitro. Indeed, we found that tumor cells cultured in the presence of both cytokines increased the percentage of CSC characteristics in comparison with control conditions (Fig. 4a) . We also tested whether this could be prevented by neutralizing monoclonal antibodies. The data indicate that indeed, the frequency of CSCs is lower when both the IL-6 and the TGF-b signaling pathways are disrupted (Fig. 4b) . However, when TC-1 tumorbearing mice were treated with monoclonal antibodies against IL-6 and/or TGF-b, we did not observe any effect on the The strength of the anti-SOX2 immune responses was evaluated by means of an in vivo CTL assay. Briefly, na€ ıve female C57BL/6 mice were immunized once or twice with SOX2-TM mRNA. Five days after the last immunization, an in vivo CTL assay was performed. Chicken ovalbumin-immunized mice were used as a positive control. (e, f) To assess the efficacy of in vivo SOX2 targeting, mice bearing subcutaneous TC-1 tumors were treated according to the experiment schedule shown in (a). Briefly, the animals were immunized three times with E7-TM, SOX2-TM or E7-SOX2-TM mRNA and tumor growth and survival were monitored until Day 98 post tumor inoculation. Median survival time values are shown in brackets. Data pooled from two independent experiments are shown (untreated n 5 9, E7-TM n 5 8, SOX2-TM n 5 9, E7-SOX2-TM n 5 9). Statistical analysis: (b) one-way ANOVA followed by Turkey's multiple comparisons test, *** significant at p < 0.001, * significant at p < 0.05; (c) unpaired t test, * significant at p < 0.05; (f) log-rank test; *** significant at p < 0.001, ns: nonsignificant. To test the effect of anti-IL-6 and anti-TGF-b blockade on CSCs, blocking monoclonal antibodies against IL-6 (50 lg/mL), TGF-b (50 lg/mL) or both were added to the cell culture. All tested conditions were cultured in the presence of recombinant IL-6 (50 ng/mL) and TGF-b (10 ng/mL) that were added to the culture 0.5 hr after the antibodies. After 48 hr of culture, cancer stem cell staining was performed. Data shown are pooled from 3 independent experiments. The bars correspond to mean values 6 SEM. (c) To test the efficacy of anti-IL-6 and anti-TGF-b blockade in vivo, TC-1 tumor-bearing mice were treated with blocking monoclonal antibodies against IL-6 (200 lg/mL) and/or TGF-b (200 lg/mL) as shown on the experiment schedule. One day after the last antibody injection, tumors were isolated and cancer stem cell staining was performed. Data shown are pooled from 3 independent experiments. The bars correspond to mean values 6 SEM. (d) To test the combination of IL-6/TGF-b blockade with E7-TM vaccine, the TC-1 tumor-bearing mice were subjected to treatment with E7-TM with or without monoclonal antibodies blocking IL-6 and/or TGF-b (see scheme shown in Fig. 2c ). Tumor growth was monitored with use of a digital caliper. Curves correspond to the mean tumor volume in function of time. (e) Survival was monitored until Day 100 post tumor inoculation. Median survival time values are shown in brackets. Data shown are pooled from two independent experiments (untreated n 5 12, E7-TM n 5 11, anti-IL6 n 5 6, anti-TGFb n 5 7, anti-IL61anti-TGFb n 5 7, E7-TM1anti-IL6 n 5 12, E7-TM1anti-TGFb n 5 11, E7-TM1anti-IL61anti-TGFb n 5 12). Statistical analysis: (a, b, c) one-way ANOVA followed by Turkey's multiple comparisons test, * significant at p < 0.05, ns: nonsignificant; (e) log-rank test *** significant at p < 0.001, ns: nonsignificant.
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presence of CSCs in vivo. Knowing that IL-6 and TGF-b are also engaged in regulation of MDSCs and Tregs, we also checked the number of MDSCs and Tregs upon treatment with anti-IL-6 and/or anti-TGF-b antibodies. Again, we did not observe any significant differences in the immune infiltrate between nontreated and treated animals (Supporting Information, Fig. 4) .
Accordingly, the combination of the E7-TM vaccine with blocking monoclonal antibodies against IL-6 and/or TGF-b did not result in an improved therapeutic outcome (Figs. 4d  and 4e ).
Simultaneous targeting of inhibitory checkpoint molecules IL-6 and TGF-b improves the therapeutic outcomes of the mRNA-based anticancer immunotherapy
To overcome resistance associated with treatment with single-pronged agents, we combined the three therapeutic approaches tested in this work: (i) E7-TM immunization, (ii) blockade of inhibitory checkpoint molecules and (iii) interference with the IL-6/TGF-b pathways. We treated TC-1 tumor-bearing mice with E7-TM and a combination of blocking antibodies against IL-6, TGF-b, PD-1, TIM-3 or LAG-3 (Figs. 5a and 5b and Supporting Information, Fig. 5 ).
We found that E7-TM mRNA vaccine together with a simultaneous blockade of TGF-b, IL-6, PD-1, TIM-3 and LAG-3 significantly improved the therapeutic control of the longestablished primary tumors leading to a complete rejection of tumors in 23% of treated mice.
Taken together, this experiment shows that simultaneous targeting soluble factors in the TME and immune checkpoint molecules has a synergistic effect and significantly improves therapeutic outcomes of the anticancer therapy compared to single therapies.
Discussion
Metastatic cancer remains an incurable disease for majority of patients. Here, we demonstrate that irrespective of the number of vaccinations, long-established TC-1 tumors develop multiple resistance mechanisms leading to tumor relapse. We report that CTL-mediated tumor debulking is associated with amplification of less differentiated tumor cells. Moreover, we show that the vaccine-induced CTLs highly express multiple inhibitory checkpoint molecules and have impaired function in vivo. In this work, we show that disrupting the IL-6/TFG-b pathway together with the reactivation of suppressed effector cells by blocking the immune (Fig. 2c) . Briefly, the mice were immunized three times with E7-TM mRNA and 3 days after the second immunization, monoclonal antibodies against PD-1, TIM-3, LAG-3, TGF-b or IL-6 were administered intraperitoneally (200 lg/antibody/mouse). Three doses of antibodies were administered with 4-day intervals. Tumor growth was monitored three times a week with use of a digital caliper. Curves correspond to the mean tumor volume in function of time. (b) Survival was monitored until Day 100 post tumor inoculation. Median survival time values are shown in brackets. Data shown are pooled from two independent experiments (untreated n 5 12, E7-TM n 5 11, E7-TM 1 anti-IL6 1 anti-TGFb n 5 12, E7-TM 1 CPIs n 5 11, E7-TM 1 CPIs 1 anti-IL6 n 5 7, E7-TM 1 CPIs 1 anti-TGFb n 5 6, E7-TM 1 CPIs 1 anti-IL6 1 anti-TGFb n 5 13). Statistical analysis: (b) log-rank test *** significant at p < 0.001, ** significant at p < 0.01, * significant at p < 0.05, ns: nonsignificant.
checkpoint molecules resulted in a significant reduction of tumor volume and lead to a prolonged survival of treated animals.
Despite the unprecedented progress in clinical outcomes obtained during the last decade, anticancer immunotherapies are still not able to induce a durable tumor rejection and prevent tumor relapse in majority of patients. 4, 38 In our previous study we evaluated the E7-TM (TriMix) vaccine in the context of TC-1 tumor model. 30 We demonstrated that clinically more relevant, long-established tumors relapse after a period of efficient tumor regression. Therefore, in this work, we decided to first investigate whether tumor regrowth could be prevented by continued therapy with E7-TM mRNA. Our data show that irrespective of the number of vaccinations, tumors regrow leading to exhaustion and death of treated mice. We therefore hypothesized that the TC-1 tumors develop adaptive resistance mechanism(s) that allow them to escape the immune control.
In the first instance, we isolated the TILs and looked at their exhaustion profile. Our ex vivo data demonstrated that >80% of E7-specific tumor-infiltrating T cells co-expressed PD-1, TIM-3 and LAG-3. Therefore, we decided to investigate the combination of E7-TM with antibodies blocking these immune checkpoint molecules in a shifted treatment regimen. Here, we report that within the context of longestablished TC-1 tumor, such a combination did not improve the therapeutic outcomes of treated mice.
Next, we investigated the role of CSCs in the regrowing TC-1 tumors, as it is postulated that these cells are responsible for tumor relapse and metastasis formation due to their stem celllike nature. So far, several preclinical and clinical studies reported amplification of CSCs upon chemotherapy 39, 40 or radiotherapy. 41, 42 Here, we showed that irrespective of the type of anticancer therapy, tumor debulking led to an increase in the percentage of CSCs as detected ex vivo in tumor nodules. Importantly, consistent with our findings, Landsberg et al. suggested that anticancer immunotherapy with use of adoptive T cell transfer can also lead to tumor dedifferentiation as a result of a strong proinflammatory TME. 3 Interestingly, the human immune system seems to have the capacity to target some pluripotency genes. Spisek et al. described that patients in a premalignant state of multiple myeloma develop both cell-mediated and humoral immune responses against SOX2 antigen. 21 Similarly, Dhodapkar et al. discovered the natural occurrence of OCT3/4 T-cell responses in healthy donors. 20 Based on these reports, we decided to test the expression of the key stemness-associated transcription factor SOX2 upon the therapy with E7-TM mRNA and then further investigated the possibility of targeting SOX2-expressing tumor cells. To our best knowledge, two studies have so far addressed the feasibility of SOX2 targeting. Favaro et al. demonstrated a significant therapeutic benefit of SOX2 peptide vaccination in combination with temozolomide in a murine model of oligodendroglioma. 43 Our data, however-in accordance with a recent study by Polakova et al. 36 -indicate that the induced immune responses do not lead to therapeutic benefit in the TC-1 tumor model when combined with E7-TM mRNA vaccine, possibly due to lover MHC class I expression, making the CSCs "invisible" to cytotoxic T cells. 44 Of note, several research groups reported that the cancer cell dedifferentiation process, in which nonstem tumor cells acquire the phenotype of stem cells may lie at the basis of the CSC amplification. 45 In this context, a growing body of evidence confirms that cancer cells can dedifferentiate and acquire stemness, not necessarily as a result of an anticancer therapy itself, but rather in a TME-dependent manner.
46,47 A suppressive TME not only allows tumor cells to dodge the defense systems of the host but, to a large extent, promote tumor progression and metastasis by regulating the tumor stemness via hypoxia, IL-6 and TGF-b. [24] [25] [26] Accordingly, elevated levels of IL-6 are associated with poor prognosis in breast, colon and lung cancer. 48, 49 Similarly, TGF-b has been shown to increase the number of CSCs. 50 Interestingly, the use of blocking anti-IL-6 antibodies was shown to prevent the conversion of nonstem cancer cells into CSCs in vitro. 24 Similarly, suppression of TGF-b prevented therapeutic resistance and tumor relapse in triple negative breast cancer patient-derived xenograft model. 39 We therefore wanted to check whether blockade of IL-6 and/or TGF-b could have an impact on the number of CSCs. In contrast to in vitro data, the ex vivo experiments indicate that these blocking antibodies do not have an impact on the numbers of CSCs in subcutaneous TC-1 tumor model. Interestingly, although both IL-6 and TGF-b exert multidimensional effects on immune cells and surrounding tissues, we did not find any significant changes in the numbers of the suppressive immune cells (i.e., MDSC or Tregs). 51, 52 It is estimated that one-fourth to one-third of the patients with objective responses to checkpoint inhibitors will relapse even when receiving continued therapy.
2 Therefore, it is becoming increasingly accepted that combination therapies might prove advantageous for tumor killing and counteracting relapse. For that reason, we decided to combine the E7-TM mRNA vaccine with a triple blockade of inhibitory checkpoint molecules (PD-1, TIM-3 and LAG-3) and the inhibition of IL-6/TGF-b pathways. We observed that such a hexatherapy leads to a significant reduction in the tumor volume and tumor rejection in some individuals. Importantly, we and others demonstrated that the local tumor environment determines the response to the treatment and that orthotopically located tumors are more difficult to eradicate that their genetically identical ectopic counterparts. 30, 53 More preclinical data will therefore be needed to validate these findings in other tumor models with a particular focus on orthotopic tumor location (the orthotopic TC-1 model has been validated by ours and two other groups, i.e., Sandoval et al. and Sun et al.). 30, 54, 55 Although in this study we did not observe any signs of toxicity after administrating three different immune checkpoint blockade inhibitors, systematic preclinical toxicity studies need to be performed to ensure the safety of such an approach and before embarking on clinical studies.
In this work, we confirm the hypothesis that tumors develop acquired resistance mechanisms in response to therapy. Our data indicates that-apart from efficient antitumor immunity-there is an urgent clinical need to simultaneously target the adaptive tumor escape by counteracting the T-cell exhaustion and interrupting the cross-talk of tumor cells with tumor-promoting environment.
